With nineteen issued patents, 290 published original papers, and thousands of citations in biochemistry literature, Alan R. Saltiel ranks among the most influential scientists in biology and biochemistry. After receiving a degree in Zoology from Duke University, and a Ph.D. in Biochemistry from the University of North Carolina, Saltiel conducted research surrounding thyroid-stimulating hormones, and the relationship to thyroid cancer. As a post-doctoral fellow, Saltiel began investigating insulin, and signaling pathways in insulin action. Saltiel’s research targeted drug discovery activities in diabetes, obesity, and cancer; he was responsible for pre-clinical studies on troglitazone: the first thiazolidinedione approved for the treatment of type 2 diabetes.
Saltiel has served as Director of the University of Michigan Life Sciences Institute since 2001, in addition to John Jacob Abel Professor of Life Sciences. In 2015, Saltiel created the Institute for Diabetes and Metabolic Health at the University of California, San Diego, while serving as a Professor of Medicine and Pharmacology.
Saltiel has received numerous awards throughout his career, including the Rosalyn Yalow Research and Development Award from the American Diabetes Association, Hirschl Award, and the John Jacob Abel Award from ASPET. He is a member of the Institute of Medicine, and a Fellow of the American Association for the Advancement of Science.
Saltiel will be the featured keynote speaker at CMHC’S Regional Conference Series in San Diego, delivering an address titled “Deep Dive Into Metabolic Health: Obesity, Inflammation, and Type 2 Diabetes.”
